Literature DB >> 20716640

From NPC therapeutic target identification to potential treatment strategy.

Ming-Ying Lan1, Chi-Long Chen, Kuan-Ting Lin, Sheng-An Lee, Wu-Lung R Yang, Chun-Nan Hsu, Jaw-Ching Wu, Ching-Yin Ho, Jin-Ching Lin, Chi-Ying F Huang.   

Abstract

Nasopharyngeal carcinoma (NPC) is relatively rare in Western countries but is a common cancer in southern Asia. Many differentially expressed genes have been linked to NPC; however, how to prioritize therapeutic targets and potential drugs from unsorted gene lists remains largely unknown. We first collected 558 upregulated and 993 downregulated NPC genes from published microarray data and the primary literatures. We then postulated that conversion of gene signatures into the protein-protein interaction network and analyzing the network topologically could provide insight into key regulators involved in tumorigenesis of NPC. Of particular interest was the presence of cliques, called fully connected subgraphs, in the inferred NPC networks. These clique-based hubs, connecting with more than three queries and ranked higher than other nodes in the NPC protein-protein interaction network, were further narrowed down by pathway analysis to retrieve 24 upregulated and 6 downregulated bottleneck genes for predicting NPC carcinogenesis. Moreover, additional oncogenes, tumor suppressor genes, genes involved in protein complexes, and genes obtained after functional profiling were merged with the bottleneck genes to form the final gene signature of 38 upregulated and 10 downregulated genes. We used the initial and final NPC gene signatures to query the Connectivity Map, respectively, and found that target reduction through our pipeline could efficiently uncover potential drugs with cytotoxicity to NPC cancer cells. An integrative Web site (http://140.109.23.188:8080/NPC) was established to facilitate future NPC research. This in silico approach, from target prioritization to potential drugs identification, might be an effective method for various cancer researches.

Entities:  

Mesh:

Year:  2010        PMID: 20716640     DOI: 10.1158/1535-7163.MCT-09-0966

Source DB:  PubMed          Journal:  Mol Cancer Ther        ISSN: 1535-7163            Impact factor:   6.261


  11 in total

1.  Identify potential drugs for cardiovascular diseases caused by stress-induced genes in vascular smooth muscle cells.

Authors:  Chien-Hung Huang; Jin-Shuei Ciou; Shun-Tsung Chen; Victor C Kok; Yi Chung; Jeffrey J P Tsai; Nilubon Kurubanjerdjit; Chi-Ying F Huang; Ka-Lok Ng
Journal:  PeerJ       Date:  2016-09-28       Impact factor: 2.984

2.  A preclinical evaluation of thiostrepton, a natural antibiotic, in nasopharyngeal carcinoma.

Authors:  Yen-Bin Hsu; Ming-Chin Lan; Yu-Lun Kuo; Chi-Ying F Huang; Ming-Ying Lan
Journal:  Invest New Drugs       Date:  2019-04-16       Impact factor: 3.850

3.  MicroRNA-129-5p suppresses nasopharyngeal carcinoma lymphangiogenesis and lymph node metastasis by targeting ZIC2.

Authors:  Dan Yu; Guang-Hong Han; Xue Zhao; Xueshibojie Liu; Kai Xue; Di Wang; Cheng-Bi Xu
Journal:  Cell Oncol (Dordr)       Date:  2019-12-28       Impact factor: 6.730

4.  Gene expression-based chemical genomics identifies potential therapeutic drugs in hepatocellular carcinoma.

Authors:  Ming-Huang Chen; Wu-Lung R Yang; Kuan-Ting Lin; Chia-Hung Liu; Yu-Wen Liu; Kai-Wen Huang; Peter Mu-Hsin Chang; Jin-Mei Lai; Chun-Nan Hsu; Kun-Mao Chao; Cheng-Yan Kao; Chi-Ying F Huang
Journal:  PLoS One       Date:  2011-11-07       Impact factor: 3.240

5.  Gene Expression Profiling and Pathway Network Analysis Predicts a Novel Antitumor Function for a Botanical-Derived Drug, PG2.

Authors:  Yu-Lun Kuo; Chun-Houh Chen; Tsung-Hsien Chuang; Wei-Kai Hua; Wey-Jinq Lin; Wei-Hsiang Hsu; Peter Mu-Hsin Chang; Shih-Lan Hsu; Tse-Hung Huang; Cheng-Yan Kao; Chi-Ying F Huang
Journal:  Evid Based Complement Alternat Med       Date:  2015-04-20       Impact factor: 2.629

6.  BRCA-Monet: a breast cancer specific drug treatment mode-of-action network for treatment effective prediction using large scale microarray database.

Authors:  Chifeng Ma; Hung-I Chen; Mario Flores; Yufei Huang; Yidong Chen
Journal:  BMC Syst Biol       Date:  2013-12-09

Review 7.  Giving Drugs a Second Chance: Overcoming Regulatory and Financial Hurdles in Repurposing Approved Drugs As Cancer Therapeutics.

Authors:  J Javier Hernandez; Michael Pryszlak; Lindsay Smith; Connor Yanchus; Naheed Kurji; Vijay M Shahani; Steven V Molinski
Journal:  Front Oncol       Date:  2017-11-14       Impact factor: 6.244

8.  Podoplanin, a Potential Therapeutic Target for Nasopharyngeal Carcinoma.

Authors:  Yen-Bin Hsu; Chi-Ying F Huang; Kuan-Ting Lin; Yu-Lun Kuo; Ming-Chin Lan; Ming-Ying Lan
Journal:  Biomed Res Int       Date:  2019-06-20       Impact factor: 3.411

9.  In silico identification of potential targets and drugs for non-small cell lung cancer.

Authors:  Chien-Hung Huang; Min-You Wu; Peter Mu-Hsin Chang; Chi-Ying Huang; Ka-Lok Ng
Journal:  IET Syst Biol       Date:  2014-04       Impact factor: 1.615

10.  Drug repositioning discovery for early- and late-stage non-small-cell lung cancer.

Authors:  Chien-Hung Huang; Peter Mu-Hsin Chang; Yong-Jie Lin; Cheng-Hsu Wang; Chi-Ying F Huang; Ka-Lok Ng
Journal:  Biomed Res Int       Date:  2014-08-18       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.